Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF06263276 · 1 trial · 1 indication
Psoriatic skin thickness was measured using a 20 megahertz (MHz) high frequency sonograph. Serial A-scans were composed and presented on a monitor as a section of the skin.
| Arm | Type | Description |
|---|---|---|
| One Arm | EXPERIMENTAL | Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment |
| Name | Type | Description |
|---|---|---|
| PF06263276 | DRUG | 4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD |
| Vehicle | OTHER | Active ingredient-free vehicle to 4% solution |
| 2%Tofacitinib Ointment | DRUG | Daily Dosage: approximately 4 mg tofacitinib |
| Daivonex | DRUG | Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg |
| Daivonex Ointment | DRUG | Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg |
Inclusion Criteria: * Healthy male and/or female subjects age 18 years and older, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical l...
PF06263276 is an investigational small molecule being studied for the treatment of psoriasis vulgaris, a form of plaque psoriasis. It is being developed as a topical drug and is currently in Phase 1 clinical development. The drug is not yet approved and remains under investigation.
PF06263276 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational topical treatment for psoriasis vulgaris.
PF06263276 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to evaluate the drug in patients with psoriasis vulgaris, but further studies are needed before it can be considered for approval.
PF06263276 has been studied in one completed Phase 1 clinical trial with the identifier NCT02193815. This was a 12-day study conducted in Germany that enrolled 15 participants with psoriasis vulgaris. The trial was randomized, double-blind, and uncontrolled, and it evaluated the topical drug in adult patients.
PF06263276 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of psoriasis vulgaris. The drug has completed a Phase 1 trial, but it has not yet received regulatory approval and remains under investigation for safety and efficacy.